Lytix Biopharma AS (DE:6BG) has released an update.
Lytix Biopharma AS has successfully raised NOK 111.3 million through a private placement and a retail offering, settling the share loan arrangement with Saturn Invest by redelivering over 1.3 million shares. This financial maneuver supports Lytix’s innovative endeavors in cancer treatment, positioning the biotech firm for future growth. Investors keen on biotech advancements may find this a promising development.
For further insights into DE:6BG stock, check out TipRanks’ Stock Analysis page.